← Back to Search

Other

Experimental Arm for Attention Deficit Hyperactivity Disorder (ADHD) (ADHD Trial)

Phase 2 & 3

Recruiting

Research Sponsored by Neurocentria, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Has a primary diagnosis of ADHD according to the DSM-5 classification, confirmed with MINI using DSM-5 probes

Male or female, 13-17 years of age at screening

Timeline

Screening 3 weeks

Treatment Varies

Follow Up over 6 weeks

Awards & highlights

ADHD Trial Summary

This trial aims to determine if NRCT-101SR is effective and safe in treating teenagers with ADHD.

Who is the study for?

This trial is for young people aged 13-17 who have been diagnosed with ADHD. The specific eligibility criteria to join the study are not provided, but typically participants must meet certain health standards and cannot be taking conflicting medications.Check my eligibility

What is being tested?

The trial is testing NRCT-101SR, a medication intended to treat ADHD in adolescents. Participants will either receive NRCT-101SR or a placebo (a substance with no therapeutic effect) to compare effectiveness and safety.See study design

What are the potential side effects?

While the exact side effects of NRCT-101SR are not listed, common side effects for ADHD medications can include sleep problems, decreased appetite, mood swings, and increased blood pressure or heart rate.

ADHD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with ADHD according to DSM-5.

Select...

I am between 13 and 17 years old.

ADHD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ over 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~over 6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and over 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective performance/Permanent Product Measure of Performance (PERMP-C) Math Tests

Secondary outcome measures

Core Symptoms/ADHD Rating Scale (ADHD-RS-5)

ADHD Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Experimental ArmExperimental Treatment1 Intervention

Up to 2,000 mg/day

Group II: Control ArmPlacebo Group1 Intervention

Matching placebo

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Neurocentria, Inc.Lead Sponsor

5 Previous Clinical Trials

322 Total Patients Enrolled

2 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)

243 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Guy Bar-Klein, PhDStudy DirectorNuerocentria

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to be a participant in this clinical trial?

"To qualify for inclusion in this research endeavor, potential participants must possess attention deficit hyperactivity disorder (ADHD) and fall within the age range of 13 to 17 years. A total of 160 individuals will be selected to partake in the clinical trial."

Answered by AI

Are researchers currently seeking participants for this ongoing medical study?

"As per the information available on clinicaltrials.gov, this particular trial is not currently seeking participants. The initial posting of the trial was on January 15th, 2024, and it was most recently updated on January 19th, 2024. However, it's worth noting that there are currently 167 other studies actively enrolling participants at this time."

Answered by AI